Establishing vaccine pregnancy registries and active surveillance studies in low-and middle-income countries: Experience from an observational cohort surveillance project in The Gambia

Sonali Kochhar[a,b], **Uduak Okomo**[c], **Oluwatosin Nkereuwem**[c], **Anna Shaum**[d], **Jane F. Gidudu**[d], **Mustapha Bittaye**[e], **Sidat Fofana**[f], **Musa Marena**[g], **Markieu Janneh Kaira**[h], **Beate Kampmann**[c,i], **Ashley T. Longley**[d,*]

[a]University of Washington, Seattle, USA

[b]Global Healthcare Consulting, New Delhi, India

[c]Vaccines & Immunity Theme, Medical Research Council Unit The Gambia at London School of Hygiene and Tropical Medicine, Fajara, The Gambia

[d]Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, USA

[e]Ministry of Health, Banjul, The Gambia

[f]Expanded Programme on Immunization, Ministry of Health, Kotu, The Gambia

[g]Reproductive, Maternal, Newborn Child and Adolescent Health Programme, Ministry of Health, Kanifing, The Gambia

[h]Medicines Control Agency, Kanifing, The Gambia

[i]Charité Centre for Global Health and Institute for International Health, Charité Universitatsmedizin, Berlin, Germany

Keywords

Despite significant advances in child survival, infectious diseases continue to be among the leading causes of neonatal deaths [1]. Maternal immunization is a well-recognized public

[*]Corresponding author at: Global Immunization Division, Global Health Center, Centers for Disease Control and Prevention (CDC), 1600 Clifton Rd NE, Atlanta, GA 30329. ALongley@cdc.gov (A.T. Longley).

health intervention to reduce vaccine-preventable disease-related morbidity and mortality in the pregnant woman, her foetus, and infant from tetanus, pertussis, seasonal influenza, and COVID-19 [2]. The development of new maternal vaccines against respiratory syncytial virus (RSV) and group B streptococcus (GBS) may significantly decrease the morbidity and mortality from these diseases in neonates and infants [2], with the U.S. Food and Drug Administration (FDA) approval for licensure of an RSV vaccine to be administered in pregnancy occurring in August 2023 [3].

Ongoing safety assessment of novel vaccines administered during pregnancy requires well-functioning passive and active surveillance systems to collect and assess adverse maternal and neonatal outcomes [4]. In high-income countries (HICs), regulatory authorities, such as the European Medicines Agency (EMA) and the U.S. FDA, require extensive post-authorization safety monitoring activities for products used during pregnancy, including active surveillance for safety-related events through pregnancy registries and observational cohort studies [4,5,6]. However, safety surveillance for vaccines used in pregnancy in many low- and middle-income countries (LMICs) currently relies on passive surveillance systems whose output cannot be interpreted appropriately due to lack of information on background rates of adverse events in pregnancy in general and lack of data on the number of pregnant women vaccinated as the relevant specific comparator [4,5,6].

Pregnancy registries routinely collect important outcome information for pregnant women (PW) and infants and are highly relevant to maternal vaccine safety surveillance. Like observational cohort studies, such registries also actively collect detailed vaccine or drug exposures during pregnancy. By allowing the comparison of PW exposed to a vaccine or drug and unexposed PW in the comparator cohort, data from pregnancy registries can help identify and estimate the risk of multiple maternal and neonatal outcomes associated with an exposure [5]. PW and their infants are to be followed to the end of pregnancy, or longer, to collect specific pregnancy and neonatal outcome data [5,6]. Although known to be important for improving vaccine and drug safety monitoring during pregnancy, pregnancy registries are limited or absent in most LMICs.

Data from pregnancy registries from HICs have shown that there is no evidence of risk to the foetus from vaccinating PW with currently recommended vaccines for PW (e.g., tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap), and seasonal influenza) or certain populations of PW (e.g., quadrivalent conjugate meningococcal vaccine (MenACWY), hepatitis A vaccine) [7].

Most recently, COVID-19 vaccines have also been recommended for PW. Despite the absence of clinical trial data in this population, available evidence shows that COVID-19 vaccines are effective and safe during pregnancy [8]. Pregnancy registries played a vital role in gathering these reassuring data, though most were implemented in HICs and predominantly relate to mRNA-based COVID-19 vaccines [7,8]. Additional safety data from COVID-19 vaccines used in pregnancy stem from voluntary smartphone-based active-surveillance systems and active surveillance through telephone interviews [8,9]. Further data from LMICs and for other COVID-19 vaccines not implemented in HICs are needed to establish that the reassuring safety records also apply across different geographical regions

and relating to different vaccines. Availability of comprehensive safety datasets will assist to mitigate major drivers of vaccine hesitancy among PW globally [2].

To address the evidence gap and increase awareness of the benefits of vaccines during pregnancy, an ongoing observational cohort-based surveillance program was established in 2022 in three selected high-volume antenatal clinics in The Gambia. These include the Bundung Maternal and Child Health Hospital, Fajikunda Major Health Centre, and Brikama District Hospital. These public health facilities each serve an annual birth cohort of up to 5,000 and have antenatal and obstetric facilities, EPI clinics, and offer COVID-19 vaccines. Additionally, surveillance program staff have access to relevant medical records from these facilities or referral hospitals for admitted PW.

To generate high-quality data for comparability, pooling, and sharing across settings, standardised measurements (e.g., gestational age (GA) assessment) and standardised case definitions (CDs) for key outcomes are needed [2,4,10]. Through the Global Alignment of Immunization Safety Assessment in Pregnancy (GAIA) project, 26 novel maternal and neonatal standardised CDs were developed to classify adverse events into levels of diagnostic certainty, which include guidelines for data collection and maps of disease codes across terminologies (e.g., MedDRA and ICD) [2,10,11,12]. A selection of these standardized CDs for key maternal and neonatal outcomes (i.e., maternal death, stillbirth, neonatal death, preterm birth, low birth weight, and congenital anomalies) is being utilized for the observational cohort surveillance program in The Gambia. The project outcomes were selected according to important pregnancy outcomes and in line with the World Health Organization (WHO) interest and GAIA guidance [2,13].

In this currently ongoing program, the selected key maternal and neonatal outcomes are recorded prospectively among PW vaccinated and unvaccinated with a COVID-19 vaccine, seeking routine antenatal care at the participating clinics. The objectives of the surveillance program are to generate background data on the pre-specified outcomes and evaluate whether outcomes of special interest differ between the groups. Eligible women in the surveillance program are those aged 18 years and older, in alignment with the COVID-19 guidelines in The Gambia, with access to a mobile telephone who consent to participate, including allowing medical record review, if applicable. PW in the vaccinated group must have documentation of receipt of at least one dose of a COVID-19 vaccine during the periconceptional period of 30 days before their last menstrual period (LMP). The surveillance program seeks to strengthen maternal vaccination programs and demand by informing immunization advisory groups' recommendations to vaccinate PW, supporting clinical guidance around vaccination during pregnancy, and encouraging vaccine uptake by generating local vaccine safety data to increase community trust. In the absence of a functioning pregnancy register, the program aims to manually link maternal and neonatal outcome data from maternal and child health programs with the pharmacovigilance system. The cohort platform established through this surveillance program also lays the foundation for a future electronic pregnancy registry that is functional for pharmacovigilance and therefore able to monitor the safety of already recommended and future maternal vaccines (e.g., RSV and GBS) in The Gambia, if and when available. The results of the observational

cohort-based surveillance program will be published on its completion, anticipated in early 2024. Here, we report key observations during the launch of the cohort program.

Establishing observational cohort studies among PW and pregnancy registries in LMICs requires standardization of information collected and specialized trainings for implementation staff. In The Gambia, antenatal care and maternal medical records are paper-based, often incomplete, and poorly maintained. Maternal vaccination is often not documented. Paper-based records are notoriously difficult to access systematically or link within health facilities or across systems, including the pharmacovigilance system. Key outcomes such as births, deaths, and other adverse events of special interest often occur outside of medical facilities and only come to attention during regular follow-up with the pregnant women receiving routine care. Collaboration between the immunization program and regulatory authorities is required to interpret and utilize the findings [4,5,6]. Consistently evaluating outcomes in regular practice requires additional human and financial resources, above those provided in routine antenatal care.

In most LMICs, standardised CDs and measurement of GA are not used routinely to classify maternal and neonatal outcomes. GA is an important variable, given that some maternal vaccines can be administered only during specific trimesters. GA is often not reliably recorded on paper-based antenatal cards being used in the selected facilities in The Gambia cohort program. To determine the GA, the LMP, fundal height, physical examination of the mother, or ultrasound information can be used with varying degrees of diagnostic certainty [14]. Although in The Gambian facilities LMP and fundal height are most commonly used [11], in many cases, PW do not know the exact date of their LMP; therefore, surveillance program staff need to refer to the ultrasound scan for GA estimates, if available. To address limitations of inconsistent GA documentation, facilities participating in the surveillance program are asked to proactively document GA on the antenatal cards to the best of their ability to strengthen the process and information collected.

Healthcare worker (HCW) training on medical data abstraction and application of the tools are important to ensure the reliability and consistency of data. These trainings include information on the rationale for the selected CDs, clinical presentation, causes, diagnosis, levels of diagnostic certainty for the condition of interest, use of the data abstraction tools, and case scenarios for hands-on practice. Additional trainings may be required for adverse events following immunization (AEFI) investigation and adjudication. To strengthen these capacities, trainings were provided for HCWs, the AEFI Investigation Committee, the National Causality Assessment Committee, and members of the immunization and regulatory agencies in The Gambia in December 2022.

To manually link maternal and neonatal outcome data from maternal and child health programs with the pharmacovigilance systems, stake-holder discussions on the data flow are essential at the conception of pregnancy registries to ensure data sharing in compatible formats via appropriate channels. These discussions ensure any potential safety signals can be immediately investigated and adjudicated with timely communication to mitigate any adverse consequences for the mother-infant pair, as well as to the vaccination program [15]. In The Gambia, it was decided that the health facilities would use the routine AEFI reporting

form and the relevant maternal or neonatal outcome data collection forms for reporting the outcomes of interest to the pharmacovigilance system. The National Regulatory Authority would follow its predefined system to share the information with the local vaccine marketing authorisation holders.

The shortage of healthcare workers in LMICs and the absence of digital health records impede data collection for pregnancy surveillance via routine staff due to existing work pressure. In The Gambia, field staff from the Medical Research Council (MRC) Unit The Gambia are working closely with designated governmental data collectors on identifying and registering PW and collecting outcome data through maternal interviews and medical chart abstraction, using an electronic data collection tool. While starting with a limited electronic database developed specifically for this project, The Gambia Ministry of Health plans to transition to electronic medical records nationally, including a nationwide pregnancy registry, that would address these challenges. To ensure the sustainability of pregnancy registries, electronic tools are needed that can be incorporated into routine antenatal care. Such tools should be developed and tailored to fulfil the needs of national governments and programs. Lessons learnt from implementing a cancer registry in the country will be useful.

In summary, monitoring the safety of vaccines during pregnancy is critical for a successful maternal immunization program. Long-term investments are required to develop sustainable systems that systematically collect and link pregnancy and infant outcomes and vaccination data within the routine surveillance and pharmacovigilance systems. Other LMICs could consider the model used in The Gambia, involving an initial smaller-scale observational cohort surveillance project in select facilities while exploring mechanisms to implement a pregnancy registry nationally. Close collaboration between immunization, maternal/child health, and regulatory authorities is required to address the needs and challenges in implementing pregnancy registries to strengthen the safety monitoring of drugs and vaccines used in PW globally. The need for such monitoring tools is urgent as new vaccines for use in pregnancy are entering the market.

Data availability

No data was used for the research described in the article.

References

[1]. Perin J, Mulick A, Yeung D, Villavicencio F, Lopez G, Strong KL, et al. Global, regional, and national causes of under-5 mortality in 2000–19: an updated systematic analysis with implications for the sustainable development goals. Lancet Child Adolesc Health 2022;6(2):106–15. 10.1016/S2352-4642(21)00311-4. Erratum. In: Lancet Child Adolesc Health. 2022 Jan; 6(1):e4. [PubMed: 34800370]

[2]. Kochhar S, Edwards KM, Ropero Alvarez AM, Moro PL, Ortiz JR. Introduction of new vaccines for immunization in pregnancy - Programmatic, regulatory, safety and ethical considerations. Vaccine 2019;37(25):3267–77. 10.1016/j.vaccine.2019.04.075. [PubMed: 31072733]

[3]. FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants. Aug 21, 202Accessed on Aug 21, 2023 at https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants.

[4]. Berrueta M, Ciapponi A, Bardach A, Cairoli FR, Castellano FJ, Xiong X, Stergachis A, Zaraa S, Meulen AS, Buekens P, Scoping Review Collaboration Group. Maternal and neonatal data collection systems in low- and middle-income countries for maternal vaccines active safety surveillance systems: A scoping review. BMC Pregnancy and Childbirth 2021 Mar;17;21(1):217. 10.1186/s12884-021-03686-9. [PubMed: 33731029]

[5]. Postapproval Pregnancy Safety Studies Guidance for Industry. 2019. Accessed on June 1, 2023 at https://www.fda.gov/media/124746/download.

[6]. Guideline on the exposure to medicinal products during pregnancy: Need for post-authorisation data. 200Accessed on June 1, 2023 at https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-exposure-medicinal-products-during-pregnancy-need-post-authorisation-data_en.pdf.

[7]. Guidelines for Vaccinating Pregnant Women. 2023 3 February 2023. Accessed on May 30, 2023 at https://www.cdc.gov/vaccines/pregnancy/hcp-toolkit/guideline.

[8]. Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, CDC v-safe COVID-19 Pregnancy Registry Team. Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. New Engl J Med 2021;384(24): 2273–82. 10.1056/NEJMoa2104983. Epub 2021 Apr 21. Erratum. In: N Engl J Med. 2021 Oct 14;385(16):1536. [PubMed: 33882218]

[9]. Goruntla N, Karisetty B, Nandini N, Bhupasamudram B, Gangireddy HR, Veerabhadrappa KV, et al. Adverse events following COVID-19 vaccination among pregnant women attending primary health centers: An active-surveillance study. Vacunas 2023. 10.1016/j.vacun.2023.05.003.

[10]. Bonhoeffer J, Kochhar S, Hirschfeld S, Heath PT, Jones CE, Bauwens J, GAIA project participants. Global alignment of immunization safety assessment in pregnancy - The GAIA project. Vaccine 2016;34(49):5993–7. 10.1016/j.vaccine.2016.07.006. Epub 2016 Oct 14. [PubMed: 27751641]

[11]. Kochhar S, Clarke E, Izu A, Emmanuel Kekane-Mochwari K, Cutland CL. Immunization in pregnancy safety surveillance in low and middle-income countries- field performance and validation of novel case definitions. Vaccine 2019;37(22):2967–74. 10.1016/j.vaccine.2019.03.074. Epub 2019 Apr 20 [PubMed: 31014963]

[12]. Stuurman AL, Riera M, Lamprianou S, Perez-Vilar S, Anderson SA, Mangtani P, et al. Vaccine safety surveillance in pregnancy in low- and middle-income countries using GAIA case definitions: A feasibility assessment. Vaccine 2018;36(45):6736–43. 10.1016/j.vaccine.2018.09.033. [PubMed: 30266486]

[13]. WHO. COVID-19 vaccines. Safety surveillance of COVID-19 vaccines in pregnant and breastfeeding women, 2021. Accessed on August 28, 2023 at https://apps.who.int/iris/handle/10665/342538.

[14]. Kochhar S. Preterm Birth and Assessment of Gestational Age Companion Guide. 2022 27 October, 2022. Accessed on May 30, 2023 at https://zenodo.org/record/7273900#.Y3StSHZBzIV.

[15]. Gidudu JF, Shaum A, Habersaat K, Wilhelm E, Woodring J, Mast E, et al. An approach for preparing and responding to adverse events following immunization reported after hepatitis B vaccine birth dose administration. Vaccine 2020;38(49):7728–40. 10.1016/j.vaccine.2019.07.041. Epub 2019 Jul 20. [PubMed: 31337590]